GLP1R and metabolic dysfunction-associated steatotic liver disease: The emergence of therapies such as SGLT2i and glucagon-like peptide-1 receptor agonists offers promise for the treatment of MASLD; however, their effects on hepatic metabolites and hepatokines remain to be determined.